SHY-ONC6 for Cancer

(Luca-1 Trial)

This trial tests a new treatment called SHY-ONC6 for individuals with advanced or metastatic solid tumors. The primary goals are to determine if SHY-ONC6 is safe, tolerable, and shows any signs of combating cancer. Participants must have specific types of cancer, such as breast, colon, or lung cancer, that have not responded to other treatments. Those with advanced cancer for whom standard therapies are ineffective or unsuitable might be suitable candidates for this trial. As a Phase 1 trial, participants will be among the first to receive this new treatment, aiding researchers in understanding its effects in people.

The trial does not specify if you must stop taking your current medications, but it mentions that you cannot have concurrent anti-cancer treatment and must comply with prohibited medication restrictions. It's best to discuss your current medications with the trial team.

Research has shown that SHY-ONC6 produced promising results in early studies. These studies found that the treatment effectively fought tumors and was generally well-tolerated in animals, meaning it worked well against tumors and caused few side effects. However, since SHY-ONC6 is being tested in humans for the first time, researchers are still assessing its safety for people. Phase 1 trials primarily focus on safety and aim to determine the appropriate dose that people can handle. While the animal studies are encouraging, human trials are necessary to confirm the safety of SHY-ONC6 for people.¹²³⁴⁵

SHY-ONC6 is unique because it is taken orally and offers a new way to target cancer cells through its novel mechanism. Unlike traditional options like chemotherapy, which often involve intravenous administration and can affect both healthy and cancerous cells, SHY-ONC6 is designed to work more selectively. Researchers are particularly excited about SHY-ONC6 because it uses a dose-escalation design to identify the most effective and safest dose, potentially leading to more personalized treatment options. This targeted approach could mean fewer side effects and improved outcomes for patients.

Research has shown that SHY-ONC6, a new pill under study in this trial, produced promising results in early studies. It stopped tumors from growing and even caused them to shrink in various cancer models. The drug effectively targeted tumors and was well-tolerated in animal studies. SHY-ONC6 blocks the proteasome, a cellular component that breaks down proteins and aids cancer cell survival. These findings suggest that SHY-ONC6 could provide a new treatment option for advanced and difficult-to-treat cancers.¹²³⁶⁷